Do You Think Like the Experts? Evolving Treatment Paradigms for Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma - priME Oncology
Do You Think Like the Experts
Do You Think Like the Experts

Do You Think Like the Experts? Evolving Treatment Paradigms for Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Not a member of My prIME? Join now for instant access.

March 2016—Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) halted ongoing first-line trials of idelalisib in combination with other agents due to an increased risk of serious adverse events including death, mostly due to infections.

  • Information about the FDA’s announcement is available on the FDA Website
  • Information about the EMA’s announcement is available on the EMA Website

Do You Think Like the Experts? Evolving Treatment Paradigms for Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

View Activity

Activity Overview

Do You Think Like the Experts? Evolving Treatment Paradigms for Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma expert discussion and downloadable slides examining best practice treatment options for patients with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin lymphoma (iNHL).

Topics

Introduction
Chronic lymphocytic leukemia
Indolent non-Hodgkin lymphoma

Moderator

  • Janice Galleshaw, MDprIME Oncology
    Atlanta, Georgia

Faculty

  • Ajay Gopal, MDUniversity of Washington and
    Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States
  • John P. Leonard, MDWeill Cornell Medical College
    New York, New York, United States
  • Richard R. Furman, MDWeill Cornell Medical College
    New York, New York, United States

Target Audience

This educational activity is designed for hematologists, oncologists, and other healthcare professionals involved in the management of patients with CLL and iNHL.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss recent clinical trial data regarding the safety and efficacy of novel treatment options for CLL and iNHL
  • Employ best practices for treatment selection and integration of novel agents in patients with CLL and iNHL
  • Discuss strategies to identify and manage treatment-related adverse events to improve quality of life and outcomes
  • Identify appropriate clinical trials in which to enroll patients with CLL and iNHL
View ActivityDownload Podcast

Provider

This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This educational activity is supported by a grant from Gilead Sciences, Inc.

Activity Date

RELEASE DATE
June 24, 2015

EXPIRATION DATE
June 24, 2016